Clinical Trial

Home Reported Outcomes in C3G Study

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 19, 2025 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall Health-related Quality of Life (HRQoL) experienced by C3 glomerulopathy (C3G) patients and their caregivers. By primarily utilizing home reported outcomes (HRO) data on symptom burden and treatment usage, supplemented with patient-reported outcome (PRO) measures (collected at baseline and monthly), the study seeks to establish a new real-world data (RWD) source to understand symptom variability and HRQoL as reported by C3G patients and caregivers, including those taking iptacopan
Trial Details
NCT Number NCT07029542
Lead Sponsor Novartis Pharmaceuticals
Conditions C3 Glomerulopathy
Enrollment 100 participants
Start Date 2025-04-07
Primary Completion 2026-04-30 (estimated)
Study Completion 2026-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-06-19